Immucell Stock Performance
| ICCC Stock | USD 6.18 0.19 2.98% |
ImmuCell has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 2.04, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ImmuCell will likely underperform. ImmuCell right now retains a risk of 3.55%. Please check out ImmuCell jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to decide if ImmuCell will be following its current trending patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ImmuCell are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound fundamental indicators, ImmuCell is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 1.6 | Five Day Return (2.82) | Year To Date Return 7.52 | Ten Year Return 8.43 | All Time Return (32.14) |
Last Split Factor 1:100 | Last Split Date 1990-07-25 |
1 | Insider Trading | 11/07/2025 |
2 | Acquisition by Te Boekhorst Paul Francis Olivier of 3708 shares of ImmuCell at 4.8686 subject to Rule 16b-3 | 12/02/2025 |
3 | Acquisition by Te Boekhorst Paul Francis Olivier of 2556 shares of ImmuCell at 5.003 subject to Rule 16b-3 | 12/03/2025 |
4 | ImmuCell Puts Re-Tain On Pause After FDA Letter | 12/26/2025 |
5 | ImmuCell reports preliminary Q4 results | 01/08/2026 |
6 | ImmuCell Q4 Earnings Call Highlights | 01/09/2026 |
7 | Acquisition by Tomsche David Scott of 100 shares of ImmuCell at 5.24 subject to Rule 16b-3 | 01/27/2026 |
| Begin Period Cash Flow | 978.7 K | |
| Total Cashflows From Investing Activities | -461.2 K |
ImmuCell Relative Risk vs. Return Landscape
If you would invest 624.00 in ImmuCell on October 31, 2025 and sell it today you would earn a total of 13.00 from holding ImmuCell or generate 2.08% return on investment over 90 days. ImmuCell is currently generating 0.097% in daily expected returns and assumes 3.5491% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than ImmuCell, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ImmuCell Target Price Odds to finish over Current Price
The tendency of ImmuCell Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6.18 | 90 days | 6.18 | about 32.04 |
Based on a normal probability distribution, the odds of ImmuCell to move above the current price in 90 days from now is about 32.04 (This ImmuCell probability density function shows the probability of ImmuCell Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.04 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ImmuCell will likely underperform. Additionally ImmuCell has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. ImmuCell Price Density |
| Price |
Predictive Modules for ImmuCell
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ImmuCell. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmuCell's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ImmuCell Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ImmuCell is not an exception. The market had few large corrections towards the ImmuCell's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ImmuCell, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ImmuCell within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.0083 | |
β | Beta against Dow Jones | 2.04 | |
σ | Overall volatility | 0.60 | |
Ir | Information ratio | 0.02 |
ImmuCell Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ImmuCell for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ImmuCell can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ImmuCell had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 26.49 M. Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 10.99 M. | |
| About 28.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Insider Trading |
ImmuCell Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ImmuCell Stock often depends not only on the future outlook of the current and potential ImmuCell's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ImmuCell's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.2 M | |
| Cash And Short Term Investments | 3.8 M |
ImmuCell Fundamentals Growth
ImmuCell Stock prices reflect investors' perceptions of the future prospects and financial health of ImmuCell, and ImmuCell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmuCell Stock performance.
| Return On Equity | 0.0661 | ||||
| Return On Asset | 0.0302 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 66.39 M | ||||
| Shares Outstanding | 9.05 M | ||||
| Price To Earning | 195.00 X | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 2.07 X | ||||
| Revenue | 26.49 M | ||||
| Gross Profit | 10.99 M | ||||
| EBITDA | 1.07 M | ||||
| Net Income | (2.16 M) | ||||
| Cash And Equivalents | 11.04 M | ||||
| Cash Per Share | 1.43 X | ||||
| Total Debt | 15.1 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 6.91 X | ||||
| Book Value Per Share | 3.30 X | ||||
| Cash Flow From Operations | 357.9 K | ||||
| Earnings Per Share | 0.21 X | ||||
| Market Capitalization | 54.73 M | ||||
| Total Asset | 45.1 M | ||||
| Retained Earnings | (14.16 M) | ||||
| Working Capital | 10.63 M | ||||
| Current Asset | 4.49 M | ||||
| Current Liabilities | 258.78 K | ||||
About ImmuCell Performance
By analyzing ImmuCell's fundamental ratios, stakeholders can gain valuable insights into ImmuCell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImmuCell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImmuCell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 125.94 | 114.80 | |
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Capital Employed | (0.04) | (0.04) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.07) | (0.07) |
Things to note about ImmuCell performance evaluation
Checking the ongoing alerts about ImmuCell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImmuCell help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmuCell had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 26.49 M. Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 10.99 M. | |
| About 28.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing ImmuCell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmuCell's stock is overvalued or undervalued compared to its peers.
- Examining ImmuCell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmuCell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmuCell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmuCell's stock. These opinions can provide insight into ImmuCell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |